Suppression of tumor growth with pembrolizumab only occurred in mice co‐engrafted with human immune cells and the response was abrogated when mice were pretreated with anti‐human CD8 mAb to deplete human CD8+ T cells, demonstrating human CD8+ T cells mediated the effector response following release from checkpoint inhibition. The gene discussed is CD8A; the disease is neoplasm.